Compare Huntington Ingalls Industries Inc (HII) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Heron Therapeutics Inc — how do they compare? Huntington Ingalls Industries Inc trades at $266.15 (market cap $10.44B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Huntington Ingalls Industries Inc is far larger — about 153.5× Heron Therapeutics Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Heron Therapeutics Inc for 35 Days on average.
| HII | HRTX | |
|---|---|---|
Market Cap | $10.44B | $68.01M |
Volume | 440,462 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $453.73 | $1.49 |
52-Week Low | $257.05 | $0.27 |
Typical Hold Time | 28 Days | 35 Days |
Enterprise Value | $13.37B | $174.75M |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $260.67, down 1.17% with bearish technical signals but strong fundamentals. The company shows consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders provide substantial revenue visibility. Valuation metrics appear reasonable with P/E of 15.78 and P/S of 0.79, while profitability metrics show ROE of 12.97% and net margin of 5.01%.
The investment case balances strong defense contracting fundamentals against technical weakness. Analyst consensus targets $363.67 (39% upside) with 40.7% buy ratings, though technical indicators show bearish momentum. Key risks include execution on large contracts and defense budget uncertainties, while catalysts include continued contract wins and autonomous technology expansion.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
